Mptp Model
Mptp Model - Related Videos
10:33
Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment
0 Views •
2026
This protocol establishes a behavioral phenotyping paradigm in MPTP-treated zebrafish larvae to evaluate Parkinson's disease-like motor and non-motor deficits.
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
0 Views •
Cited by 23 •
2019
We describe establishment of a murine model for Parkinson's disease using MPTP, and behavioral assessments using cylinder and open field tests to measure motor function. We then use L-DOPA as one example to show how to apply this model in the study of PD drugs.
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
0 Views •
Cited by 10 •
2014
Lipoxygenase (LOX) isozymes can generate products that may increase or decrease neuroinflammation and neurodegeneration. A gene-environment interaction study could identify LOX isozyme-specific effects. Using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of nigrostriatal damage in two LOX isozyme-deficient transgenic lines allows for comparison of the contribution of LOX isozymes on dopaminergic integrity and inflammation.
11:05
Behavioral Characterization of an Angelman Syndrome Mouse Model
0 Views •
Cited by 1 •
2023
This manuscript presents a set of highly reproducible behavioral tests to validate an Angelman syndrome mouse model.
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
0 Views •
Cited by 65 •
2013
Here, we present a systematic approach for developing physiologically relevant, sensitive and specific in vivo assays for interpreting variation in human pathology. Transient genetic manipulation via microinjection of WT and mutant human mRNA and morpholino (MO) antisense oligonucleotides harness the tractability of the developing zebrafish embryo to rapidly assay pathogenic mutations, especially, but not exclusively, in the context of human developmental disorders.
FAQs
Damage to mitochondrial complex I is the critical intracellular event linking toxin exposure to reduced dopamine signaling. When MPP+ enters dopaminergic neurons, it disrupts this complex, impairing mitochondrial function and contributing to neuronal injury. The resulting striatal dopamine deficit provides a mechanistic bridge between cellular damage and measurable motor abnormalities.
Outcomes are not fixed because symptom severity depends on species, dose, and administration protocol. Identical experimental goals may therefore produce different behavioral effects under different conditions. This variability affects the magnitude of dopamine-related motor deficits and must be considered when comparing groups or interpreting treatment effects. Reporting these factors supports meaningful behavioral conclusions.
Bradykinesia, rigidity, impaired coordination, and altered movement patterns provide complementary behavioral evidence of disrupted motor control. Together, these measures can show whether the induced dopamine deficit affects movement speed, motor function, and coordination rather than relying on a single readout. Their severity also helps characterize the model’s behavioral phenotype.
A behavioral study typically proceeds from MPTP administration to measurement of motor abnormalities, with the observed phenotype interpreted alongside the experimental dose, species, and administration protocol. Researchers can then compare movement-related outcomes across conditions, including treatment groups, to determine whether an intervention changes deficits associated with reduced striatal dopamine signaling.
Within behavioral research, the model supports investigations of motor control and disease mechanisms, as well as evaluation of potential treatments. Its value lies in connecting a defined neurochemical change in the striatum with observable movement abnormalities. This allows researchers to examine both how motor behavior is disrupted and whether an intervention modifies that disruption.
Results can reveal changes in movement speed, rigidity, coordination, and overall movement patterns, but they should not be interpreted independently of model conditions. Because species, dose, and administration protocol influence symptom severity, behavioral outcomes are most informative when those variables are documented and considered during analysis of disease-related or treatment-related effects.